{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:12:22Z","timestamp":1791623542753,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xiamen Amoytop Biotech Co., LTD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chemotherapy-induced neutropenia (CIN) is usually managed by recombinant human granulocyte colony stimulating factor (rhG-CSF) and pegylated rhG-CSF (PEG-rhG-CSF). This study evaluated the efficacy and safety of telpegfilgrastim, a novel Y-shaped PEG-rhG-CSF, for CIN prophylaxis in patients with non-small cell lung cancer (NSCLC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a multicentre, randomized, open-label, active-controlled non-inferiority study. Patients with NSCLC who received 1\u20134 chemotherapy cycles of docetaxel plus carboplatin were randomized 1:1:1 to receive telpegfilgrastim 2\u00a0mg, 33\u00a0\u00b5g\/kg or control drug (rhG-CSF [Topneuter\u00ae]\u00a0in cycle 1 of chemotherapy, rhG-CSF\u00a0[Topneuter\u00ae] or PEG-rhG-CSF\u00a0[Xinruibai\u00ae] per patients\u2019 choice in cycles 2\u20134 of chemotherapy). The primary endpoint was duration of grade 4 neutropenia in cycle 1 of chemotherapy. Secondary endpoints included duration of grade 4 neutropenia in cycles 2\u20134 of chemotherapy, incidence of febrile neutropenia (FN), duration and incidence of \u2265 grade 3 neutropenia, dynamic change of absolute neutrophil count from baseline and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>From October 16, 2020, to September 1, 2021, 133 patients were randomized to telpegfilgrastim 2\u00a0mg (<jats:italic>n<\/jats:italic>\u2009=\u200944), 33\u00a0\u00b5g\/kg (<jats:italic>n<\/jats:italic>\u2009=\u200945) and control group (<jats:italic>n<\/jats:italic>\u2009=\u200944). In cycle 1 of chemotherapy, the mean duration of grade 4 neutropenia in telpegfilgrastim 2\u00a0mg, 33\u00a0\u00b5g\/kg groups and control group were 0.02\u00a0day, 0.09\u00a0day and 0.16\u00a0day, respectively. The least square mean differences versus control group were -0.14\u00a0day [95% confidence interval [CI]: -0.35, 0.06] for telpegfilgrastim 2\u00a0mg group and -0.06\u00a0day [95% CI: -0.26, 0.15] for telpegfilgrastim 33\u00a0\u00b5g\/kg group. which met the prespecified non-inferiority margin of 1\u00a0day. Incidence of grade 4 neutropenia, incidence of FN and duration of \u2265 grade 3 neutropenia in cycles 1\u20134 of chemotherapy was similar between telpegfilgrastim groups and control group. Telpegfilgrastim was well tolerated, and the incidence of adverse events were comparable with control group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study demonstrated that telpegfilgrastim 2\u00a0mg or 33\u00a0\u03bcg\/kg was non-inferior to rhG-CSF (Topneuter\u00ae) and PEG-rhG-CSF (Xinruibai\u00ae) for the management of CIN in patients with NSCLC. In particular, a 2\u00a0mg fixed dose of\u00a0telpegfilgrastim\u00a0presents a more convenient administration option.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04466137\" ext-link-type=\"uri\">NCT04466137<\/jats:ext-link>, July 10, 2020.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13736-6","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:01:41Z","timestamp":1742216501000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer:\u00a0a multicentre, randomized, phase 3 study"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaqiu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhuan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengqiu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"3","key":"13736_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"13736_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584\u201390.","journal-title":"Chin Med J (Engl)"},{"issue":"10299","key":"13736_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","volume":"398","author":"AA Thai","year":"2021","unstructured":"Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet. 2021;398(10299):535\u201354.","journal-title":"Lancet"},{"key":"13736_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s12272-021-01312-y","volume":"44","author":"H-Y Min","year":"2021","unstructured":"Min H-Y, Lee H-Y. Mechanisms of resistance to chemotherapy in non-small cell lung cancer. Arch Pharm Res. 2021;44:146\u201364.","journal-title":"Arch Pharm Res"},{"key":"13736_CR5","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/1759-7714.14544","volume":"13","author":"X-S Sun","year":"2022","unstructured":"Sun X-S, Wang Z, Ren S-H, Zhang H-L, Liu L-J, Du H-B, et al. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: a multicenter, prospective, randomized study. Thorac Cancer. 2022;13:2429\u201335.","journal-title":"Thorac Cancer"},{"key":"13736_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cllc.2015.12.002","volume":"17","author":"C Zhou","year":"2016","unstructured":"Zhou C, Huang Y, Wang D, An C, Zhou F, Li Y, et al. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC). Clin Lung Cancer. 2016;17:119\u201327.","journal-title":"Clin Lung Cancer"},{"key":"13736_CR7","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, et al. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:2475\u201384.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"13736_CR8","first-page":"896","volume":"17","author":"Y Ba","year":"2020","unstructured":"Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L, et al. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy. China Anti-Cancer Association Cancer Biol Med. 2020;17:896\u2013909.","journal-title":"China Anti-Cancer Association Cancer Biol Med"},{"key":"13736_CR9","doi-asserted-by":"crossref","unstructured":"Xie J, Cao J, Wang JF, Zhang BH, Zeng XH, Zheng H, et al. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study. Breast Cancer Res Treat. 2018;168(2):389\u201399.","DOI":"10.1007\/s10549-017-4609-6"},{"key":"13736_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.21147\/j.issn.1000-9604.2017.05.04","volume":"29","author":"Y Qin","year":"2017","unstructured":"Qin Y, Han X, Wang L, Du P, Yao J, Wu D, et al. A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia. Chin J Cancer Res. 2017;29:402\u201310.","journal-title":"Chin J Cancer Res"},{"key":"13736_CR11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/CAD.0b013e3283610b5d","volume":"24","author":"Y-K Shi","year":"2013","unstructured":"Shi Y-K, Chen Q, Zhu Y-Z, He X-H, Wang H-Q, Jiang Z-F, et al. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study. Anticancer Drugs. 2013;24:641\u20137.","journal-title":"Anticancer Drugs"},{"key":"13736_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000345626","volume":"58","author":"B-B Yang","year":"2012","unstructured":"Yang B-B, Savin MA, Green M. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes. Chemotherapy. 2012;58:387\u201398.","journal-title":"Chemotherapy"},{"key":"13736_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14:29\u201335.","journal-title":"Ann Oncol"},{"key":"13736_CR14","first-page":"68","volume":"22","author":"Y Song","year":"2013","unstructured":"Song Y, Shi Y, Zhang C, Zhou S, Yao J, Gui L, et al. Phase I clinical pharmacokinetics and pharmacodynamics study of Y-type polyethylene glycol recombinant human granulocyte colony-stimulating factor injection. Chin J New Drugs. 2013;22:68\u201374.","journal-title":"Chin J New Drugs"},{"issue":"08","key":"13736_CR15","first-page":"928","volume":"22","author":"SY Zhou","year":"2013","unstructured":"Zhou SY, Shi YK, Gui L, et al. A randomized, open-label, single-dose, self-controlled, dose-escalation phase I clinical trial of Y-shaped polyethylene glycol recombinant human granulocyte colony-stimulating factor. Chin J New Drugs. 2013;22(08):928\u201336.","journal-title":"Chin J New Drugs"},{"key":"13736_CR16","doi-asserted-by":"publisher","first-page":"572077","DOI":"10.3389\/fbioe.2020.572077","volume":"8","author":"M Kumari","year":"2020","unstructured":"Kumari M, Sahni G, Datta S. Development of site-specific PEGylated granulocyte colony stimulating factor with prolonged biological activity. Front Bioeng Biotechnol. 2020;8:572077.","journal-title":"Front Bioeng Biotechnol"},{"key":"13736_CR17","unstructured":"TelpegfilgrastimInjectionApprovedforMarketingbyChinaNMPA-News. https:\/\/www.ccfdie.org\/en\/gzdt\/webinfo\/2023\/07\/1681345923386528.htm. Accessed 17 Aug 2023."},{"issue":"5","key":"13736_CR18","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","volume":"20","author":"EA Griffiths","year":"2022","unstructured":"Griffiths EA, Roy V, Alwan L, et al. NCCN guidelines\u00ae insights: hematopoietic growth factors, version 1.2022. J Natl Compr Canc Netw. 2022;20(5):436\u201342. https:\/\/doi.org\/10.6004\/jnccn.2022.0026.","journal-title":"J Natl Compr Canc Netw."},{"key":"13736_CR19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Cancer Therapy Evaluation Program, 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"13736_CR20","first-page":"2045","volume":"23","author":"G Kourlaba","year":"2015","unstructured":"Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2015;23:2045\u201351.","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"13736_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bcp.15507","volume":"89","author":"X Huang","year":"2023","unstructured":"Huang X, Li S, Shi W, Wang Y, Wan X, He J, et al. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). Br J Clin Pharmacol. 2023;89:372\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"13736_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23:525\u201345.","journal-title":"Support Care Cancer"},{"key":"13736_CR23","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:1178\u201384.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"13736_CR24","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3816\/CCC.2010.n.013","volume":"9","author":"JR Hecht","year":"2010","unstructured":"Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, et al. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer. 2010;9:95\u2013101.","journal-title":"Clin Colorectal Cancer"},{"key":"13736_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1186\/s12885-021-08258-w","volume":"21","author":"R Mahtani","year":"2021","unstructured":"Mahtani R, Crawford J, Flannery SM, Lawrence T, Schenfeld J, Gawade PL. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety. BMC Cancer. 2021;21:621.","journal-title":"BMC Cancer"},{"key":"13736_CR26","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:3187\u2013205.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"47","key":"13736_CR27","first-page":"8","volume":"2011","author":"MS Aapro","year":"1990","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer Oxf Engl. 1990;2011(47):8\u201332.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"13736_CR28","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","volume":"18","author":"FV Fossella","year":"2000","unstructured":"Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18:2354\u201362.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"key":"13736_CR29","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","volume":"18","author":"FA Shepherd","year":"2000","unstructured":"Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O\u2019Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18:2095\u2013103.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"13736_CR30","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:1589\u201397.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"13736_CR31","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","volume":"21","author":"F Fossella","year":"2003","unstructured":"Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non\u2013small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016\u201324.","journal-title":"J Clin Oncol"},{"key":"13736_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1759-7714.14233","volume":"13","author":"X Ji","year":"2022","unstructured":"Ji X, Xu L, Pan P, Xu Z, Wang A, Li Y. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer. Thorac Cancer. 2022;13:117\u201325.","journal-title":"Thorac Cancer"},{"key":"13736_CR33","doi-asserted-by":"publisher","first-page":"80020","DOI":"10.18632\/oncotarget.18145","volume":"8","author":"F Zhang","year":"2017","unstructured":"Zhang F, LingHu R, Zhan X, Li R, Feng F, Gao X, et al. Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients. Oncotarget. 2017;8:80020\u20138.","journal-title":"Oncotarget"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13736-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13736-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:01:50Z","timestamp":1742216510000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13736-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13736"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13736-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by ethics committee of National Cancer Center\/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and\u00a0all the participating hospitals. This\u00a0study\u00a0was conducted in accordance with the International Council for Harmonization guidelines on Good Clinical Practice, China\u2019s regulatory requirements and the ethical principles of Declaration of Helsinki. Written informed consents were obtained from all patients before study enrolment. This study was registered at ClinicalTrials.gov, number: NCT04466137.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Li Sun is the employee of Xiamen Amoytop Biotech Co., LTD. All other authors declared no related conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"490"}}